Newcastle disease virus suppresses antigen presentation via inhibiting IL-12 expression in dendritic cells. / æ–°åŸŽç–«ç— æ¯’é€šè¿‡æŠ‘åˆ¶æ ‘çªçŠ¶ç»†èƒžç™½ä»‹ç´ 12的表达抑制抗原递呈.

As a potential vectored vaccine, Newcastle disease virus (NDV) has been subject to various studies for vaccine development, while relatively little research has outlined the immunomodulatory effect of the virus in antigen presentation. To elucidate the key inhibitory factor in regulating the interaction of infected dendritic cells (DCs) and T cells, DCs were pretreated with the NDV vaccine strain LaSota as an inhibitor and stimulated with lipopolysaccharide (LPS) for further detection by enzyme-linked immunosorbent assay (ELISA), flow cytometry, immunoblotting, and quantitative real-time polymerase chain reaction (qRT-PCR). The results revealed that NDV infection resulted in the inhibition of interleukin (IL)-12p40 in DCs through a p38 mitogen-activated protein kinase (MAPK)|-dependent manner, thus inhibiting the synthesis of IL-12p70, leading to the reduction in T cell proliferation and the secretion of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and IL-6 induced by DCs. Consequently, downregulated cytokines accelerated the infection and viral transmission from DCs to T cells. Furthermore, several other strains of NDV also exhibited inhibitory activity. The current study reveals that NDV can modulate the intensity of the innate|‒|adaptive immune cell crosstalk critically toward viral invasion improvement, highlighting a novel mechanism of virus-induced immunosuppression and providing new perspectives on the improvement of NDV-vectored vaccine.

Photochemical inactivation as an alternative method to produce a whole-cell vaccine for uropathogenic Escherichia coli (UPEC).

Uropathogenic Escherichia coli (UPEC) is the primary causative agent of lower urinary tract infection (UTI). UTI presents a serious health risk and has considerable secondary implications including economic burden, recurring episodes, and overuse of antibiotics. A safe and effective vaccine would address this widespread health problem and emerging antibiotic resistance. Killed, whole-cell vaccines have shown limited efficacy to prevent recurrent UTI in human trials. We explored photochemical inactivation with psoralen drugs and UVA light (PUVA), which crosslinks nucleic acid, as an alternative to protein-damaging methods of inactivation to improve whole-cell UTI vaccines. Exposure of UPEC to the psoralen drug AMT and UVA light resulted in a killed but metabolically active (KBMA) state, as reported previously for other PUVA-inactivated bacteria. The immunogenicity of PUVA-UPEC as compared to formalin-inactivated UPEC was compared in mice. Both generated high UPEC-specific serum IgG titers after intramuscular delivery. However, using functional adherence as a measure of surface protein integrity, we found differences in the properties of PUVA- and formalin-inactivated UPEC. Adhesion mediated by Type-1 and P-fimbriae was severely compromised by formalin but was unaffected by PUVA, indicating that PUVA preserved the functional conformation of fimbrial proteins, which are targets of protective immune responses. In vitro assays indicated that although they retained metabolic activity, PUVA-UPEC lost virulence properties that could negatively impact vaccine safety. Our results imply the potential for PUVA to improve killed, whole-cell UTI vaccines by generating bacteria that more closely resemble their live, infectious counterparts relative to vaccines generated with protein-damaging methods. IMPORTANCE: Lower urinary tract infection (UTI), caused primarily by uropathogenic Escherichia coli, represents a significant health burden, accounting for 7 million primary care and 1 million emergency room visits annually in the United States. Women and the elderly are especially susceptible and recurrent infection (rUTI) is common in those populations. Lower UTI can lead to life-threatening systemic infection. UTI burden is manifested by healthcare dollars spent (1.5 billion annually), quality of life impact, and resistant strains emerging from antibiotic overuse. A safe and effective vaccine to prevent rUTI would address a substantial healthcare issue. Vaccines comprised of inactivated uropathogenic bacteria have yielded encouraging results in clinical trials but improvements that enhance vaccine performance are needed. To that end, we focused on inactivation methodology and provided data to support photochemical inactivation, which targets nucleic acid, as a promising alternative to conventional protein-damaging inactivation methods to improve whole-cell UTI vaccines.

TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences.

After three years of the SARS-CoV-2 pandemic, the search and availability of relatively low-cost benchtop therapeutics for people not at high risk for a severe disease are still ongoing. Although vaccines and new SARS-CoV-2 variants reduce the death toll, the long COVID-19 along with neurologic symptoms can develop and persist even after a mild initial infection. Reinfections, which further increase the risk of sequelae in multiple organ systems as well as the risk of death, continue to require caution. The spike protein of SARS-CoV-2 is an important target for both vaccines and therapeutics. The presence of disulfide bonds in the receptor binding domain (RBD) of the spike protein is essential for its binding to the human ACE2 receptor and cell entry. Here, we demonstrate that thiol-reducing peptides based on the active site of oxidoreductase thioredoxin 1, called thioredoxin mimetic (TXM) peptides, can prevent syncytia formation, SARS-CoV-2 entry into cells, and infection in a mouse model. We also show that TXM peptides inhibit the redox-sensitive HIV pseudotyped viral cell entry. These results support disulfide targeting as a common therapeutic strategy for treating infections caused by viruses using redox-sensitive fusion. Furthermore, TXM peptides exert anti-inflammatory properties by lowering the activation of NF-κB and IRF signaling pathways, mitogen-activated protein kinases (MAPKs) and lipopolysaccharide (LPS)-induced cytokines in mice. The antioxidant and anti-inflammatory effects of the TXM peptides, which also cross the blood-brain barrier, in combination with prevention of viral infections, may provide a beneficial clinical strategy to lower viral infections and mitigate severe consequences of COVID-19.

PBITV3 : A robust and comprehensive tool for screening pathogenic proteomes for drug targets and prioritizing vaccine candidates.

Rise of life-threatening superbugs, pandemics and epidemics warrants the need for cost-effective and novel pharmacological interventions. Availability of publicly available proteomes of pathogens supports development of high-throughput discovery platforms to prioritize potential drug-targets and develop testable hypothesis for pharmacological screening. The pipeline builder for identification of target (PBIT) was developed in 2016 and updated in 2021, with the purpose of accelerating the search for drug-targets by integration of methods like comparative and subtractive genomics, essentiality/virulence and druggability analysis. Since then, it has been used for identification of drugs and vaccine targets, safety profiling of multiepitope vaccines and mRNA vaccine construction against a broad-spectrum of pathogens. This tool has now been updated with functionalities related to systems biology and immuno-informatics and validated by analyzing 48 putative antigens of Mycobacterium tuberculosis documented in literature. PBITv3 available as both online and offline tools will enhance drug discovery against emerging drug-resistant infectious agents. PBITv3 can be freely accessed at http://pbit.bicnirrh.res.in/.

Preparing for the Next Pandemic: Increased Expression of Interferon-Stimulated Genes After Local Administration of Nasalferon or HeberNasvac.

HeberNasvac, a therapeutic vaccine for chronic hepatitis B, is able to safely stimulate multiple Toll-like receptors, increasing antigen presentation in vitro and in a phase II clinical trial (Profira) in elderly volunteers who were household contacts of respiratory infection patients. Thus, a new indication as a postexposure prophylaxis or early therapy for respiratory infections has been proposed. In this study, we evaluated the expression of several interferon-stimulated genes (ISGs) after mucosal administration of HeberNasvac and compared this effect with the nasal delivery of interferon alpha 2b (Nasalferon). Molecular studies of blood samples of 50 subjects from the Profira clinical trial who were locally treated with HeberNasvac or Nasalferon and concurrent untreated individuals were compared based on their relative mRNA expression of OAS1, ISG15, ISG20, STAT1, STAT3, and DRB1-HLA II genes. In most cases, the gene expression induced by HeberNasvac was similar in profile and intensity to the expression induced by Nasalferon and significantly superior to that observed in untreated controls. The immune stimulatory effect of HeberNasvac on ISGs paved the way for its future use as an innate immunity stimulator in elderly persons and immunocompromised subjects or as part of Mambisa, a nasal vaccine to prevent severe acute respiratory syndrome coronavirus 2 infection.

Humoral immunity is not altered in overweight pregnant Crioulo mares / Imunidade humoral não é alterada em éguas Crioulas gestantes com sobrepeso

Both pregnancy and obesity can influence significant changes in the immune system. On this basis, the present study proposes to evaluate the humoral immune response of overweight pregnant mares in response to a commercial vaccine. Thirty pregnant Crioulo mares were separated according to body condition score (BCS) into overweight (BCS≥7/9) or lean-control (BCS= 5-6/9). In each group, the animals were subdivided into vaccinated and controls. The mares were vaccinated against EHV-1 in two doses spaced 21 days apart and had their blood collected monthly, for five months, for antibody evaluation. Both vaccinated groups had an increase in specific neutralizing antibodies after the vaccine. However, after the second dose, there was no increase in antibodies in any of the groups. Vaccinated overweight and lean-control mares did not differ at any time point. Therefore, this study demonstrated that obesity does not influence the humoral immune response in pregnant Crioulo mares.(AU)

Tanto a gestação quanto a obesidade podem influenciar o desenvolvimento de alterações significativas no sistema imune, portanto, o presente estudo teve como objetivo avaliar a resposta imune humoral de éguas gestantes com sobrepeso em resposta a uma vacina comercial. Trinta éguas Crioulas gestantes foram separadas de acordo com o escore de condição corporal (ECC) em éguas com sobrepeso (ECC≥7/9) e éguas controles (ECC=5-6/9) e, ainda, em cada grupo, os animais também foram separados em vacinados e controles. As éguas foram vacinadas contra o EHV-1 em duas doses com intervalo de 21 dias, sendo realizadas coletas de sangue mensalmente durante cinco meses para avaliação de anticorpos neutralizantes. Ambos os grupos vacinados tiveram aumento de anticorpos neutralizantes específicos após a vacina, porém, após a segunda dose, não foi observado aumento de anticorpos em nenhum dos grupos. Nenhuma diferença foi observada entre éguas vacinadas com sobrepeso e as éguas controles em nenhum momento. Assim, este estudo demonstrou que a obesidade não é um fator que influencia a resposta imune humoral de éguas Crioulas gestantes.(AU)

Coletiva de imprensa: Governo de SP anuncia novas medidas no combate ao coronavírus

Saiba mais em: www.saopaulo.sp.gov.br/coronavirus/planosp

Informe diário de evidências COVID-19: busca realizada em 16 de junho de 2020 / COVID-19 daily evidence report: search conducted on June 16, 2020

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referente ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 15 artigos. Foram encontrados 8 artigos e 15 protocolos.

Coronavírus: como estão às pesquisas para medicamentos e vacinas?

Live from WHO Headquarters: COVID-19 daily press briefing 04 May 2020

Originally broadcast live on 04 May 2020, the daily press briefing on coronavirus COVID-19, direct from WHO Headquarters, Geneva Switzerland with Dr Tedros WHO Director-General, Dr Micheal Ryan, Executive Director of the Health Emergencies Programme, and Dr Maria Van Kerkhove, Technical lead COVID-19, WHO Health Emergencies Programme.

Usando a imunologia de sistemas para entender os mecanismos moleculares de doenças e vacinas / Using systems immunology to understand the molecular mechanisms of diseases and vaccines

Nas últimas décadas, dados relacionados com a saúde humana, desde informações clínicas e epidemiológicas até imagens médicas e experimentos ômicos, foram gerados e acumulados em uma quantidade sem precedentes na história. Um campo novo de pesquisa chamado "Imunologia de Sistemas" emergiu para tentar integrar, analisar, interpretar e predizer os mecanismos moleculares de doenças e vacinas. Esta tese mostra diversas aplicações da Imunologia de Sistemas no estudo de arboviroses, vacina da gripe, câncer, tuberculose, pneumonia, artrite, dentre outros. Também mostra o desenvolvimento de ferramentas computacionais amigáveis que permitem com que qualquer cientista, sem conhecimento prévio de bioinformática, possa realizar análises de Imunologia de Sistemas. Os achados das análises forneceram novas hipóteses e insights que, ao serem testados e validados experimentalmente, melhoram nosso entendimento sobre os processos imunológicos por trás da vacinação e de doenças humanas

Influência da Hidroquinona nas respostas imune humoral e celular induzida por vacina viral com proteína recombinante (Dengue) / The Influence of Hydroquinone in the humoral and cellular immune responses elicited by vaccination with Dengue envelope recombinant Protein

A fumaça do cigarro apresenta mais de 8700 substâncias identificadas, as quais já foram relacionadas com o desenvolvimento das mais variadas doenças. Dentre elas, uma substância relevante neste contexto de toxicidade do cigarro é a hidroquinona (HQ), gerada após a biotransformação do benzeno inalado. A HQ apresenta atividades relacionadas com a imunossupressão das respostas imune inata e adaptativa, observados mais no contexto in vitro e parcamente no in vivo; contudo, nenhum estudo ainda trouxe a abordagem do efeito da exposição à HQ sobre a resposta induzida por vacinação. Sendo assim, será que a exposição à fumaça do cigarro ou à HQ influenciaria na resposta de células B e geração de anticorpos induzidas por imunizações com vacinas anti-virais? Observamos que, após a exposição diária com 2500 ppm de HQ (equivalente a um maço de cigarro fumado / dia) por 8 semanas e vacinação com proteína recombinante codificadora do domínio III do Envelope do vírus da Dengue sorotipo 2 (EDIII) mais o adjuvante Alum, houve uma "tendência" para menores títulos de IgG total e IgG1 específicos à EDIII em camundongos C57BL/6. Análises histológicas revelaram um menor número de folículos e redução significativa de suas áreas no baço do grupo HQ em comparação com os não expostos. Para entendermos o efeito da HQ sobre a resposta humoral, realizamos uma análise de dados públicos de transcriptoma obtidas de amostras de sangue de humanos. Curiosamente, observamos que a HQ regula positivamente genes relacionados com a ativação de células B, assim como a migração e quimiotaxia de neutrófilos e outros leucócitos. Como é sabido que existe uma população de neutrófilos (N2) com a capacidade de auxiliar as respostas de células B, hipotetizamos que essas células poderiam disparar um mecanismo imunocompensatório que aumenta os títulos de anticorpos no grupo HQ

The cigarette smoke has more than 8700 harmful substances related to the occurrence of the most varied diseases. Among them, a relevant substance is the hydroquinone (HQ), generated upon the biotransformation of inhaled benzene. In vitro and in vivo analyses have demonstrated that HQ can suppress both innate and adaptive immune responses. However, no study has approached the effect of the HQ exposure on the vaccination-induced response. Thus, would the exposure to the cigarette smoke or HQ influence the B-cell and antibody responses elicited by immunizations with antiviral vaccines? We observed a "tendency" to lower titers of IgG total and IgG1 anti-EDIII in mice daily exposed to 2,500 ppm of HQ for 8 weeks and vaccinated. Histological analyses revealed a smaller number of follicles and a significant reduction in their area in the HQ group in comparison to their counterparts. In order to understand the effect of the HQ on the humoral response, we performed an analysis of public transcriptome data derived from human blood samples. We observed that the HQ up-regulates the expression of genes related to B cell activation as well as the migration and chemotaxis of neutrophils and other leukocytes. Considering that N2 neutrophils have the ability to help the B cell response, we have hypothesized that the HQ exposure may trigger an immunocompensatory effect, increasing the humoral response

Enhancing immune effects of a DNA vaccine against kidney cancer using CD40L as an adjuvant

The use of specific combinations of antigens and adjuvant represents a promising approach for increasing the immunogenicity of DNA vaccines. In the present study, we evaluated the immunity and antitumor effects of DNA vaccines with G250 as the target antigen in a mouse model of renal cell carcinoma. We constructed two recombinant plasmids, pVAX1-G250 and pVAX1-CD40L. The recombinant plasmids were injected into mice by intramuscular injection and electrical pulse stimulation. ELISA and ELISPOT experiments were performed to evaluate the corresponding humoral and cellular immune responses following immunization. To further investigate the antitumor potential of the DNA vaccines, we established a tumor-bearing mouse model expressing G250 target antigen. Our results showed that immunization with the combination of the two plasmids exerted the strongest anti-tumor effects. Therefore, our findings demonstrated the effectiveness of CD40L as an adjuvant for DNA vaccines and highlighted the promising use of these vaccines for the treatment of tumors.

Ocorrência do subtipo B do vírus da imunodeficiência felina em gatos domésticos da região sul do estado do Rio Grande do Sul, Brasil / Occurrence of subtype B of the feline immunodeficiency virus in domestic cats from the south region of Rio Grande do Sul state, Brazil

No Brasil existem poucos estudos sobre a ocorrência da infecção pelo vírus da imunodeficiência felina (FIV), assim como a determinação dos subtipos circulantes, o que é indispensável para o desenvolvimento de vacinas e novos testes diagnósticos. O presente trabalho investigou a ocorrência da infecção pelo FIV entre os anos de 2010 e 2011 em gatos domésticos submetidos a atendimento clínico na cidade de Pelotas e região. Amostras de sangue total de 70 animais, incluindo suspeitos (28) ou não suspeitos (42) da infecção pelo FIV, foram submetidas à reação de PCR nested. Os resultados indicaram uma frequência de infecção de 15,7% (11/70) e a análise dos fatores associados (sexo, idade e condição clínica) evidenciou uma maior ocorrência em gatos com idade superior a 10 anos e acometidos por infecções crônicas e recidivantes. Oito amostras positivas na PCR nested foram submetidas a sequenciamento genômico e somente o subtipo B foi detectado na região estudada.

In Brazil there are few studies on the occurrence of the feline immunodeficiency virus (FIV) infection and its subtypes, which are essential for the development of vaccines and new diagnostic tests. The present study investigated the occurrence of the FIV infection between 2010 and 2011 in domestic cats submitted to medical attendance in the city of Pelotas and nearby area. Total blood samples of seventy cats, suspected (28) or not (42) of infection by FIV were analyzed by nested PCR in order to perform a diagnosis. The results pointed to a FIV infection frequency of 15.7% (11/70) and the analysis of the risk factors related to infection (sex, age and clinical condition) evidenced a greater occurrence in cats up to 10 years of age with chronic and recurrent infections. Eight samples found positive by nested PCR were submitted to DNA sequencing indicating that only the subtype B was detected in the studied region.

Mapeo computacional de epítopos de células B presentes en el virus del dengue / B-cell epitopes mapping of dengue virus

Dengue es una infección viral de importancia en salud pública. El desarrollo de una vacuna va a depender del conocimiento de aquello epítopos que neutralicen la infección y por ello, se generaron e identificaron computacionalmente aquellos epítopos lineales consenso de células B presentes en el virus del dengue, a partir de los datos depositados en la base de datos Immune Epitope Database (IEDB). Posteriormente, se agruparon en bloques de ocho aminoácidos por cada serotipo mediante el programa Nomad, y cada uno de ellos fue reevaluado con el programa BepiPred para determinar su antigenicidad. Se lograron postular 172 de los 1.239 obtenidos en la IEDB.

Dengue virus has emerged as a major public health problem. An epitope-based approach to the development of vaccines, and for this reason, based on Immune Epitope Database database (IEDB), linear consensus B-cell epitopes were computationally generated and identified from dengue virus. Then, amino acids were grouped into blocks of eight amino acids per serotype through Nomad program. Each block was evaluated using BepiPred for determining antigenic prediction. 172 out of 1239 were obtained from IEDB.

Diversidad antigénica de las vacunas antiparotiditicas / Antigenic diversity of vaccines againts mumps

La parotiditis es una enfermedad infecciosa inmunoprevenible  causada por el virus de la parotiditis, miembro del género Rubulavirus, familia Paramyxoviridae, del cual se conocen 12 genotipos confirmados, designados como A-L y otro nuevo genotipo designado como M. Las vacunas anti-parotiditis por lo general,  se fabrican empleando virus vivo atenuado de alguno de estos genotipos y están  disponibles como monovalente (parotiditis) y trivalente (sarampión-rubéola-parotiditis). A pesar de los programas de vacunación implementados por muchos países, se han presentado brotes de parotiditis en forma epidémica en la cual se ha detectado co-circulación de genotipos entre poblaciones vacunadas. Entre las posibles explicaciones  están: el fracaso primario a la vacunación, pérdida de efectividad secundaria e infección por virus heterólogos. Como consecuencia la Organización Mundial de la Salud (OMS) ha recomendado estudios moleculares epidemiológicos, que incluya la genotipificación de cepas circulantes del virus de la parotiditis, como parte del programa de vigilancia. Esto permitirá una mayor información de la distribución de los genotipos en todo el mundo, contribuyendo a la vigilancia de la parotiditis y posiblemente en la reformulación de vacunas más eficaces. Esta revisión muestra la importancia que tiene la caracterización molecular  o genotipificación del virus de la parotiditis, con el propósito de comprender y explicar el comportamiento epidemiológico de esta enfermedad que ha sido ampliamente controlada por la aplicación sistemática de la vacuna a nivel mundial.

Mumps is a vaccine-preventable infectious disease, caused by mumps virus, member of Rubulavirus genus, Paramyxoviridae family, has been classified into 12 confirmed genotypes, designated as A-L and one proposed genotype, M. Usually the anti-mumps vaccines are manufactured using attenuated live virus genotypes and any of these are available as monovalent (mumps) and trivalent (measles-mumps-rubella). Although vaccination programs implemented by many countries, there have been outbreaks of mumps in epidemic form, in which has been detected co-circulation of genotypes among vaccinated populations. Possible explanations are: the primary vaccination failure, loss of high effectiveness and heterologous virus infection. Because of this, the World Health Organization (WHO) has recommended molecular epidemiological studies, including genotyping of circulating strains of mumps virus as part of the monitoring program. This information will allow greater distribution of genotypes worldwide, contributing to monitoring and possibly mumps reformulating more effective vaccines. This review shows the importance of molecular characterization and genotyping of mumps virus, in order to understand and explain the epidemiological behavior of the disease has been largely controlled by the systematic application of the vaccine worldwide.

Dimensionamiento del sistema de microfiltración para la producción de la Vacuna Pertussis elaborada en el Instituto Nacional de Higiene “Rafael Rangel” / Microfiltration sistem dimension for using in Pertussis Vaccine toxin production in the Instituto Nacional de Higiene "Rafael Rangel"

Se evaluó el uso de la tecnología de Flujo de Filtración Tangencial (FFT), para obtener la Vacuna Pertussis Celular a partir de cultivos de la bacteria Bordetella pertussis, usando el proceso de Microfiltración (MF) a objeto de recuperar el paquete celular. Se determinaron las características de los filtros, condiciones de trabajo y el dimensionamiento del equipo a adquirir para la nueva producción in dustrial de Vacuna Pertussis Celular. Se evaluaron el flujo y tiempo de proceso, rendimiento y las características del producto obtenido. Utilizando cultivos con Vacuna Pertus sis en un equipo de filtración de laboratorio, diseñado para producir el efecto de FFT. Se seleccionó las membranas tipo cassettes, formato Suspended Screen, porosidad 0,2 μm, como las adecuadas para el proceso de MF, ya que mostraron un 100% de recuperación del paquete celular sin transmisión de células al filtrado y con un flujo promedio de filtrado de 54.00 L/m2h. Estos resultaron permitieron dimensionar, considerando las variables a utilizar en la nueva producción industrial (Volumen 650 Litros, Tiempo de Procesos, 3 a 4 horas), el área de filtración del equipo de MF a adquirir, estimado en 20 m² .

Tangential Flow Filtration (TFF) technology was evaluated to process Whole Cell Pertussis Vaccine which is produced by Bordetella pertussis bacterium. Microfiltration (MF) is used to recovery cells to produ ce the vaccine. MF pro - cesses was evaluated to specify the filters and corresponding critical process parameters to scale-up the application. As part of the evaluation, flow rate, processing time, yield and product attributes were characterized. The cell harvest con taining the Whole Cell Pertussis was processed using a laboratory scale TFF system designed to pro duct the TFF effect. The evaluation demonstrated that a cassette in suspended screen format and membrane with 0.2μm pore is the right selection for the MF step. It showed 100% of cell recovery without cell transmission to the filtrate and average process flux of 54.00 L/m2h. These results were used to scale-up the application to process the industrial volume of 650 liters in 3 hours of processing time. Membrane area sizing of MF to be acquired is estimated in 20 m².